{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T07:16:07Z","timestamp":1791098167952,"version":"4.1.0"},"reference-count":233,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001824","name":"Grantov\u00e1 Agentura \u010cesk\u00e9 Republiky","doi-asserted-by":"crossref","award":["GA22-16389S"],"award-info":[{"award-number":["GA22-16389S"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Institute Virology and Bacteriology","award":["LX22NPO5103"],"award-info":[{"award-number":["LX22NPO5103"]}]},{"DOI":"10.13039\/501100010099","name":"Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010099","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Genomic alterations and enormous monoclonal immunoglobulin production cause multiple myeloma to heavily depend on proteostasis mechanisms, including protein folding and degradation. These findings support the use of proteasome inhibitors for treating multiple myeloma and mantle cell lymphoma. Myeloma treatment has evolved, especially with the availability of new drugs, such as proteasome inhibitors, into therapeutic strategies for both frontline and relapsed\/refractory disease settings. However, proteasome inhibitors are generally not effective enough to cure most patients. Natural resistance and eventual acquired resistance led to relapsed\/refractory disease and poor prognosis. Advances in the understanding of cellular proteostasis and the development of innovative drugs that also target other proteostasis network components offer opportunities to exploit the intrinsic vulnerability of myeloma cells. This review outlines recent findings on the molecular mechanisms regulating cellular proteostasis pathways, as well as resistance, sensitivity, and escape strategies developed against proteasome inhibitors and provides a rationale and examples for novel combinations of proteasome inhibitors with FDA-approved drugs and investigational drugs targeting the NRF1 (NFE2L1)-mediated proteasome bounce-back\u00a0response, redox homeostasis, heat shock response, unfolding protein response, autophagy, and VCP\/p97 to increase proteotoxic stress, which can improve the efficacy of antimyeloma therapy based on proteasome inhibitors.<\/jats:p>","DOI":"10.1007\/s10238-025-01713-z","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T03:43:05Z","timestamp":1748230985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Impact of proteostasis workload on sensitivity to proteasome inhibitors in multiple myeloma"],"prefix":"10.1007","volume":"25","author":[{"given":"Jindrich","family":"Sedlacek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"1713_CR1","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046. https:\/\/doi.org\/10.1038\/nrdp.2017.46.","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"1713_CR2","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3322\/caac.21252","volume":"64","author":"G Bianchi","year":"2014","unstructured":"Bianchi G, Anderson KC. Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back. CA Cancer J Clin. 2014;64(6):422\u201344. https:\/\/doi.org\/10.3322\/caac.21252.","journal-title":"CA Cancer J Clin"},{"issue":"13","key":"1713_CR3","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1182\/blood-2008-08-172734","volume":"113","author":"G Bianchi","year":"2009","unstructured":"Bianchi G, Oliva L, Cascio P, et al. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood. 2009;113(13):3040\u20139. https:\/\/doi.org\/10.1182\/blood-2008-08-172734.","journal-title":"Blood"},{"issue":"4","key":"1713_CR4","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","volume":"67","author":"S Meister","year":"2007","unstructured":"Meister S, Schubert U, Neubert K, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 2007;67(4):1783\u201392. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-2258.","journal-title":"Cancer Res"},{"issue":"1","key":"1713_CR5","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1074\/jbc.M509126200","volume":"281","author":"SB Qian","year":"2006","unstructured":"Qian SB, Princiotta MF, Bennink JR, Yewdell JW. Characterization of rapidly degraded polypeptides in mammalian cells reveals a novel layer of nascent protein quality control. J Biol Chem. 2006;281(1):392\u2013400. https:\/\/doi.org\/10.1074\/jbc.M509126200.","journal-title":"J Biol Chem"},{"issue":"6779","key":"1713_CR6","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/35008096","volume":"404","author":"U Schubert","year":"2000","unstructured":"Schubert U, Ant\u00f3n LC, Gibbs J, et al. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature. 2000;404(6779):770\u20134. https:\/\/doi.org\/10.1038\/35008096.","journal-title":"Nature"},{"key":"1713_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.semcdb.2003.12.008","volume":"15","author":"CM Dobson","year":"2004","unstructured":"Dobson CM. Principles of protein folding, misfolding and aggregation. Semin Cell Dev Biol. 2004;15:3\u201316. https:\/\/doi.org\/10.1016\/j.semcdb.2003.12.008.","journal-title":"Semin Cell Dev Biol"},{"issue":"6","key":"1713_CR8","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1083\/jcb.201312042","volume":"204","author":"A Ruggiano","year":"2014","unstructured":"Ruggiano A, Foresti O, Carvalho P. Quality control: ER-associated degradation: protein quality control and beyond. J Cell Biol. 2014;204(6):869\u201379. https:\/\/doi.org\/10.1083\/jcb.201312042.","journal-title":"J Cell Biol"},{"issue":"10","key":"1713_CR9","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1083\/jcb.201906047","volume":"218","author":"Z Sun","year":"2019","unstructured":"Sun Z, Brodsky JL. Protein quality control in the secretory pathway. J Cell Biol. 2019;218(10):3171\u201387. https:\/\/doi.org\/10.1083\/jcb.201906047.","journal-title":"J Cell Biol"},{"key":"1713_CR10","first-page":"286","volume":"34","author":"DM Benbrook","year":"2012","unstructured":"Benbrook DM, Long A. Integration of autophagy, proteasomal degradation, unfolded protein response and apoptosis. Exp Oncol. 2012;34:286\u201397.","journal-title":"Exp Oncol"},{"key":"1713_CR11","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1126\/science.1209038","volume":"334","author":"P Walter","year":"2011","unstructured":"Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science. 2011;334:1081\u20136. https:\/\/doi.org\/10.1126\/science.1209038.","journal-title":"Science"},{"issue":"6","key":"1713_CR12","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2174\/1568009614666140804154511","volume":"14","author":"QP Dou","year":"2014","unstructured":"Dou QP, Zonder JA. Overview of proteasome inhibitor-based anticancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. Curr Cancer Drug Targets. 2014;14(6):517\u201336. https:\/\/doi.org\/10.2174\/1568009614666140804154511.","journal-title":"Curr Cancer Drug Targets"},{"issue":"5","key":"1713_CR13","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1189\/jlb.1011497","volume":"92","author":"S Cenci","year":"2012","unstructured":"Cenci S, Oliva L, Cerruti F, et al. Pivotal Advance: Protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors. J Leukoc Biol. 2012;92(5):921\u201331. https:\/\/doi.org\/10.1189\/jlb.1011497.","journal-title":"J Leukoc Biol"},{"issue":"1","key":"1713_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.bbamcr.2013.08.012","volume":"1843","author":"M Schmidt","year":"2014","unstructured":"Schmidt M, Finley D. Regulation of proteasome activity in health and disease. Biochim Biophys Acta. 2014;1843(1):13\u201325. https:\/\/doi.org\/10.1016\/j.bbamcr.2013.08.012.","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"1713_CR15","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","volume":"120","author":"P Moreau","year":"2012","unstructured":"Moreau P, Richardson PG, Cavo M, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012;120(5):947\u201359. https:\/\/doi.org\/10.1182\/blood-2012-04-403733.","journal-title":"Blood"},{"issue":"5\u20136","key":"1713_CR16","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.drudis.2010.01.008","volume":"15","author":"LR Dick","year":"2010","unstructured":"Dick LR, Fleming PE. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today. 2010;15(5\u20136):243\u20139. https:\/\/doi.org\/10.1016\/j.drudis.2010.01.008.","journal-title":"Drug Discov Today"},{"issue":"22","key":"1713_CR17","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.2174\/1381612811319220012","volume":"19","author":"D Buac","year":"2013","unstructured":"Buac D, Shen M, Schmitt S, et al. From bortezomib to other inhibitors of the proteasome and beyond. Curr Pharm Des. 2013;19(22):4025\u201338. https:\/\/doi.org\/10.2174\/1381612811319220012.","journal-title":"Curr Pharm Des"},{"issue":"5 Suppl","key":"1713_CR18","doi-asserted-by":"publisher","first-page":"676","DOI":"10.6004\/jnccn.2013.0199","volume":"11","author":"KC Anderson","year":"2013","unstructured":"Anderson KC. Therapeutic advances in relapsed or refractory multiple myeloma. J Natl Compr Canc Netw. 2013;11(5 Suppl):676\u20139. https:\/\/doi.org\/10.6004\/jnccn.2013.0199.","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"1713_CR19","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1182\/blood-2008-04-149385","volume":"112","author":"AA Argyriou","year":"2008","unstructured":"Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood. 2008;112(5):1593\u20139. https:\/\/doi.org\/10.1182\/blood-2008-04-149385.","journal-title":"Blood"},{"key":"1713_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/BTT.S24580","volume":"7","author":"A Nooka","year":"2013","unstructured":"Nooka A, Gleason C, Casbourne D, Lonial S. Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib. Biologics. 2013;7:13\u201332. https:\/\/doi.org\/10.2147\/BTT.S24580.","journal-title":"Biologics"},{"issue":"3","key":"1713_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2174\/156800911794519725","volume":"11","author":"DJ Kuhn","year":"2011","unstructured":"Kuhn DJ, Orlowski RZ, Bjorklund CC. Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs) Curr. Cancer Drug Targets. 2011;11(3):285\u201395. https:\/\/doi.org\/10.2174\/156800911794519725.","journal-title":"Cancer Drug Targets"},{"issue":"1","key":"1713_CR22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1345\/aph.1R561","volume":"47","author":"JL Thompson","year":"2013","unstructured":"Thompson JL. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma. Ann Pharmacother. 2013;47(1):56\u201362. https:\/\/doi.org\/10.1345\/aph.1R561.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"1713_CR23","doi-asserted-by":"publisher","first-page":"254","DOI":"10.2174\/156800911794519716","volume":"11","author":"BC Potts","year":"2011","unstructured":"Potts BC, Albitar MX, Anderson KC, et al. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinicaltrials. Curr Cancer Drug Targets. 2011;11(3):254\u201384. https:\/\/doi.org\/10.2174\/156800911794519716.","journal-title":"Curr Cancer Drug Targets"},{"issue":"5","key":"1713_CR24","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/sj.emboj.7601009","volume":"25","author":"S Cenci","year":"2006","unstructured":"Cenci S, Mezghrani A, Cascio P, et al. Progressively impaired proteasomal capacity during terminal plasma cell differentiation. EMBO J. 2006;25(5):1104\u201313. https:\/\/doi.org\/10.1038\/sj.emboj.7601009.","journal-title":"EMBO J"},{"issue":"3","key":"1713_CR25","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/eji.200737743","volume":"38","author":"P Cascio","year":"2008","unstructured":"Cascio P, Oliva L, Cerruti F, et al. Dampening Ab responses using proteasome inhibitors following in vivo B-cell activation. Eur J Immunol. 2008;38(3):658\u201367. https:\/\/doi.org\/10.1002\/eji.200737743.","journal-title":"Eur J Immunol"},{"issue":"7","key":"1713_CR26","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/nm1763","volume":"14","author":"K Neubert","year":"2008","unstructured":"Neubert K, Meister S, Moser K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med. 2008;14(7):748\u201355. https:\/\/doi.org\/10.1038\/nm1763.","journal-title":"Nat Med"},{"issue":"1","key":"1713_CR27","doi-asserted-by":"publisher","first-page":"6820","DOI":"10.1038\/s41467-022-34654-2","volume":"13","author":"A Vdovin","year":"2022","unstructured":"Vdovin A, Jelinek T, Zihala D, et al. The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma. Nat Commun. 2022;13(1):6820. https:\/\/doi.org\/10.1038\/s41467-022-34654-2.","journal-title":"Nat Commun"},{"issue":"12","key":"1713_CR28","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","volume":"107","author":"EA Obeng","year":"2006","unstructured":"Obeng EA, Carlson LM, Gutman DM, et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107(12):4907\u201316. https:\/\/doi.org\/10.1182\/blood-2005-08-3531.","journal-title":"Blood"},{"issue":"6","key":"1713_CR29","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1038\/leu.2009.8","volume":"23","author":"T R\u00fcckrich","year":"2009","unstructured":"R\u00fcckrich T, Kraus M, Gogel J, et al. Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells. Leukemia. 2009;23(6):1098\u2013105. https:\/\/doi.org\/10.1038\/leu.2009.8.","journal-title":"Leukemia"},{"issue":"2","key":"1713_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056132","volume":"8","author":"TB Shabaneh","year":"2013","unstructured":"Shabaneh TB, Downey SL, Goddard AL, et al. Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib. PLoS ONE. 2013;8(2): e56132. https:\/\/doi.org\/10.1371\/journal.pone.0056132.","journal-title":"PLoS ONE"},{"issue":"2","key":"1713_CR31","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/leu.2016","volume":"31","author":"B Paiva","year":"2017","unstructured":"Paiva B, Puig N, Cedena MT, et al. Differentiation stage of myeloma plasma cells: biological and clinical significance. Leukemia. 2017;31(2):382\u201392. https:\/\/doi.org\/10.1038\/leu.2016.","journal-title":"Leukemia"},{"issue":"2","key":"1713_CR32","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1182\/blood-2012-06-436220","volume":"121","author":"A Chaidos","year":"2013","unstructured":"Chaidos A, Barnes CP, Cowan G, et al. Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood. 2013;121(2):318\u201328. https:\/\/doi.org\/10.1182\/blood-2012-06-436220.","journal-title":"Blood"},{"issue":"35","key":"1713_CR33","doi-asserted-by":"publisher","first-page":"21588","DOI":"10.1073\/pnas.2001323117","volume":"117","author":"Z Sha","year":"2020","unstructured":"Sha Z, Goldberg AL. Multiple myeloma cells are exceptionally sensitive to heat shock, which overwhelms their proteostasis network and induces apoptosis. Proc Natl Acad Sci U S A. 2020;117(35):21588\u201397. https:\/\/doi.org\/10.1073\/pnas.2001323117.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1713_CR34","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.ccell.2015.09.010","volume":"24","author":"C Leung-Hagesteijn","year":"2013","unstructured":"Leung-Hagesteijn C, Erdmann N, Cheung G, et al. Xbp1s-negative tumor B cells and preplasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell. 2013;24(3):541\u20132. https:\/\/doi.org\/10.1016\/j.ccell.2015.09.010.","journal-title":"Cancer Cell"},{"issue":"19","key":"1713_CR35","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1182\/blood-2018-05-851170","volume":"132","author":"C Driessen","year":"2018","unstructured":"Driessen C, M\u00fcller R, Novak U, et al. Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma. Blood. 2018;132(19):2097\u2013100. https:\/\/doi.org\/10.1182\/blood-2018-05-851170.","journal-title":"Blood"},{"key":"1713_CR36","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ceb.2013.12.006","volume":"26","author":"EM Sontag","year":"2014","unstructured":"Sontag EM, Vonk WIM, Frydman J. Sorting out the trash: the spatial nature of eukaryotic protein quality control. Curr Opin Cell Biol. 2014;26:139\u201346. https:\/\/doi.org\/10.1016\/j.ceb.2013.12.006.","journal-title":"Curr Opin Cell Biol"},{"key":"1713_CR37","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.molcel.2020.01.010","volume":"77","author":"R Verma","year":"2020","unstructured":"Verma R, Mohl D, Deshaies RJ. Harnessing the power of proteolysis for targeted protein inactivation. Mol Cell. 2020;77:446\u201360. https:\/\/doi.org\/10.1016\/j.molcel.2020.01.010.","journal-title":"Mol Cell"},{"key":"1713_CR38","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487\u201398. https:\/\/doi.org\/10.1056\/NEJMoa043445.","journal-title":"N Engl J Med"},{"issue":"2","key":"1713_CR39","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ceb.2010.11.004","volume":"23","author":"S Cenci","year":"2011","unstructured":"Cenci S, van Anken E, Sitia R. Proteostenosis and plasma cell pathophysiology. Curr Opin Cell Biol. 2011;23(2):216\u201322. https:\/\/doi.org\/10.1016\/j.ceb.2010.11.004.","journal-title":"Curr Opin Cell Biol"},{"issue":"6","key":"1713_CR40","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.3324\/haematol.2022.282225","volume":"108","author":"X Zhou","year":"2023","unstructured":"Zhou X, Besse A, Peter J, et al. High-dose carfilzomib achieves superior antitumour activity over lowdose and recaptures response in relapsed\/refractory multiple myeloma resistant to low-dose carfilzomib by coinhibiting the \u03b22 and \u03b21 subunits of the proteasome complex. Haematologica. 2023;108(6):1628\u201339. https:\/\/doi.org\/10.3324\/haematol.2022.282225.","journal-title":"Haematologica"},{"issue":"5","key":"1713_CR41","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2017.04.023","volume":"169","author":"GA Collins","year":"2017","unstructured":"Collins GA, Goldberg AL. The Logic of the 26S Proteasome. Cell. 2017;169(5):792\u2013806. https:\/\/doi.org\/10.1016\/j.cell.2017.04.023.","journal-title":"Cell"},{"issue":"8","key":"1713_CR42","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2183\/pjab.94.021","volume":"94","author":"S Koizumi","year":"2018","unstructured":"Koizumi S, Hamazaki J, Murata S. Transcriptional regulation of the 26S proteasome by Nrf1. Proc Jpn Acad Ser B Phys Biol Sci. 2018;94(8):325\u201336. https:\/\/doi.org\/10.2183\/pjab.94.021.","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"issue":"8","key":"1713_CR43","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/cr.2016.86","volume":"26","author":"I Livneh","year":"2016","unstructured":"Livneh I, Cohen-Kaplan V, Cohen-Rosenzweig C, et al. The life cycle of the 26S proteasome: from birth, through regulation and function, and onto its death. Cell Res. 2016;26(8):869\u201385. https:\/\/doi.org\/10.1038\/cr.2016.86.","journal-title":"Cell Res"},{"issue":"2","key":"1713_CR44","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.tig.2020.09.005","volume":"37","author":"HE Kamber Kaya","year":"2021","unstructured":"Kamber Kaya HE, Radhakrishnan SK. Trash talk: mammalian proteasome regulation at the transcriptional level. Trends Genet. 2021;37(2):160\u201373. https:\/\/doi.org\/10.1016\/j.tig.2020.09.005.","journal-title":"Trends Genet"},{"issue":"1","key":"1713_CR45","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.molcel.2010.02.029","volume":"38","author":"SK Radhakrishnan","year":"2010","unstructured":"Radhakrishnan SK, Lee CS, Young P, et al. Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells. Mol Cell. 2010;38(1):17\u201328. https:\/\/doi.org\/10.1016\/j.molcel.2010.02.029.","journal-title":"Mol Cell"},{"issue":"1","key":"1713_CR46","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.molcel.2010.09.012","volume":"40","author":"J Steffen","year":"2010","unstructured":"Steffen J, Seeger M, Koch A, Kr\u00fcger E. Proteasomal degradation is transcriptionally controlled by TCF11 via an ERAD-dependent feedback loop. Mol Cell. 2010;40(1):147\u201358. https:\/\/doi.org\/10.1016\/j.molcel.2010.09.012.","journal-title":"Mol Cell"},{"issue":"4","key":"1713_CR47","doi-asserted-by":"publisher","first-page":"e00439","DOI":"10.1128\/MCB.00439-16","volume":"37","author":"L Baird","year":"2017","unstructured":"Baird L, Tsujita T, Kobayashi EH, et al. A homeostatic shift facilitates endoplasmic reticulum proteostasis through transcriptional integration of proteostatic stress response pathways. Mol Cell Biol. 2017;37(4):e00439-e516. https:\/\/doi.org\/10.1128\/MCB.00439-16.","journal-title":"Mol Cell Biol"},{"issue":"20","key":"1713_CR48","doi-asserted-by":"publisher","first-page":"10228","DOI":"10.1093\/nar\/gks827","volume":"40","author":"Y Hirotsu","year":"2012","unstructured":"Hirotsu Y, Katsuoka F, Funayama R, et al. Nrf2-MafG heterodimers contribute globally to antioxidant and metabolic networks. Nucleic Acids Res. 2012;40(20):10228\u201339. https:\/\/doi.org\/10.1093\/nar\/gks827.","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"1713_CR49","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.3390\/ijms18122772","volume":"18","author":"S Vomund","year":"2017","unstructured":"Vomund S, Sch\u00e4fer A, Parnham MJ, et al. Nrf2, the master regulator of anti-oxidative responses. Int J Mol Sci. 2017;18(12):2772. https:\/\/doi.org\/10.3390\/ijms18122772.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1713_CR50","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1365-2443.2011.01522.x","volume":"16","author":"A Kobayashi","year":"2011","unstructured":"Kobayashi A, Tsukide T, Miyasaka T, et al. Central nervous system-specific deletion of transcription factor Nrf1 causes progressive motor neuronal dysfunction. Genes Cells. 2011;16(6):692\u2013703. https:\/\/doi.org\/10.1111\/j.1365-2443.2011.01522.x.","journal-title":"Genes Cells"},{"issue":"20","key":"1713_CR51","doi-asserted-by":"publisher","first-page":"8408","DOI":"10.1073\/pnas.1019209108","volume":"108","author":"CS Lee","year":"2011","unstructured":"Lee CS, Lee C, Hu T, et al. Loss of nuclear factor E2-related factor 1 in the brain leads to dysregulation of proteasome gene expression and neurodegeneration. Proc Natl Acad Sci U S A. 2011;108(20):8408\u201313. https:\/\/doi.org\/10.1073\/pnas.1019209108.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"1713_CR52","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1111\/febs.12350","volume":"280","author":"CS Lee","year":"2013","unstructured":"Lee CS, Ho DV, Chan JY. Nuclear factor-erythroid 2-related factor 1 regulates expression of proteasome genes in hepatocytes and protects against endoplasmic reticulum stress and steatosis in mice. FEBS J. 2013;280(15):3609\u201320. https:\/\/doi.org\/10.1111\/febs.12350.","journal-title":"FEBS J"},{"issue":"18","key":"1713_CR53","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.15252\/embj.201593725","volume":"35","author":"JC Villaescusa","year":"2016","unstructured":"Villaescusa JC, Li B, Toledo EM, et al. A PBX1 transcriptional network controls dopaminergic neuron development and is impaired in Parkinson\u2019s disease. EMBO J. 2016;35(18):1963\u201378. https:\/\/doi.org\/10.15252\/embj.201593725.","journal-title":"EMBO J"},{"issue":"8","key":"1713_CR54","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1172\/JCI99042","volume":"128","author":"SR Nath","year":"2018","unstructured":"Nath SR, Yu Z, Gipson TA, et al. Androgen receptor polyglutamine expansion drives age-dependent quality control defects and muscle dysfunction. J Clin Invest. 2018;128(8):630\u20133641. https:\/\/doi.org\/10.1172\/JCI99042.","journal-title":"J Clin Invest"},{"issue":"10","key":"1713_CR55","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.3390\/ijms21103683","volume":"21","author":"J Hamazaki","year":"2020","unstructured":"Hamazaki J, Murata S. ER-resident transcription factor Nrf1 regulates proteasome expression and beyond. Int J Mol Sci. 2020;21(10):3683. https:\/\/doi.org\/10.3390\/ijms21103683.","journal-title":"Int J Mol Sci"},{"key":"1713_CR56","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.18357","volume":"5","author":"S Koizumi","year":"2016","unstructured":"Koizumi S, Irie T, Hirayama S, et al. The aspartyl protease DDI2 activates Nrf1 to compensate for proteasome dysfunction. Elife. 2016;5: e18357. https:\/\/doi.org\/10.7554\/eLife.18357.","journal-title":"Elife"},{"issue":"6","key":"1713_CR57","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1074\/jbc.RA118.006290","volume":"294","author":"JR Vangala","year":"2019","unstructured":"Vangala JR, Radhakrishnan SK. Nrf1-mediated transcriptional regulation of the proteasome requires a functional TIP60 complex. J Biol Chem. 2019;294(6):2036\u201345. https:\/\/doi.org\/10.1074\/jbc.RA118.006290.","journal-title":"J Biol Chem"},{"issue":"14","key":"1713_CR58","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.cub.2014.06.004","volume":"24","author":"Z Sha","year":"2014","unstructured":"Sha Z, Goldberg AL. Proteasome-mediated processing of Nrf1 is essential for coordinate induction of all proteasome subunits and p97. Curr Biol. 2014;24(14):1573\u201383. https:\/\/doi.org\/10.1016\/j.cub.2014.06.004.","journal-title":"Curr Biol"},{"issue":"2","key":"1713_CR59","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.chembiol.2016.12.016","volume":"24","author":"ES Weyburne","year":"2017","unstructured":"Weyburne ES, Wilkins OM, Sha Z, et al. Inhibition of the proteasome \u03b22 site sensitizes triple-negative breast cancer cells to \u03b25 inhibitors and suppresses Nrf1 activation. Cell Chem Biol. 2017;24(2):218\u201330. https:\/\/doi.org\/10.1016\/j.chembiol.2016.12.016.","journal-title":"Cell Chem Biol"},{"issue":"3","key":"1713_CR60","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.chembiol.2018.11.007","volume":"26","author":"A Besse","year":"2019","unstructured":"Besse A, Besse L, Kraus M, et al. Proteasome inhibition in multiple myeloma: head-to-head comparison of currently available proteasome inhibitors. Cell Chem Biol. 2019;26(3):340-351.e3. https:\/\/doi.org\/10.1016\/j.chembiol.2018.11.007.","journal-title":"Cell Chem Biol"},{"issue":"1","key":"1713_CR61","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041266","volume":"15","author":"G Ruvkun","year":"2023","unstructured":"Ruvkun G, Lehrbach N. Regulation and functions of the ER-associated Nrf1 transcription factor. Cold Spring Harb Perspect Biol. 2023;15(1): a041266. https:\/\/doi.org\/10.1101\/cshperspect.a041266.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"6","key":"1713_CR62","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","volume":"112","author":"R Oerlemans","year":"2008","unstructured":"Oerlemans R, Franke NE, Assaraf YG, et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood. 2008;112(6):2489\u201399. https:\/\/doi.org\/10.1182\/blood-2007-08-104950.","journal-title":"Blood"},{"issue":"1","key":"1713_CR63","doi-asserted-by":"publisher","first-page":"12788","DOI":"10.1038\/s41598-022-17239-3","volume":"12","author":"SL Downey-Kopyscinski","year":"2022","unstructured":"Downey-Kopyscinski SL, Srinivasa S, Kisselev AF. A clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax. Sci Rep. 2022;12(1):12788. https:\/\/doi.org\/10.1038\/s41598-022-17239-3.","journal-title":"Sci Rep"},{"issue":"20","key":"1713_CR64","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1091\/mbc.E20-04-0238","volume":"31","author":"A Northrop","year":"2020","unstructured":"Northrop A, Byers HA, Radhakrishnan SK. Regulation of NRF1, a master transcription factor of proteasome genes: implications for cancer and neurodegeneration. Mol Biol Cell. 2020;31(20):2158\u201363. https:\/\/doi.org\/10.1091\/mbc.E20-04-0238.","journal-title":"Mol Biol Cell"},{"issue":"1","key":"1713_CR65","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3390\/ijms21010327","volume":"21","author":"A Northrop","year":"2020","unstructured":"Northrop A, Vangala JR, Feygin A, Radhakrishnan SK. Disabling the protease DDI2 attenuates the transcriptional activity of NRF1 and potentiates proteasome inhibitor cytotoxicity. Int J Mol Sci. 2020;21(1):327. https:\/\/doi.org\/10.3390\/ijms21010327.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1713_CR66","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1182\/bloodadvances.2020003820","volume":"6","author":"T Chen","year":"2022","unstructured":"Chen T, Ho M, Briere J, et al. Multiple myeloma cells depend on the DDI2\/NRF1-mediated proteasome stress response for survival. Blood Adv. 2022;6(2):429\u201340. https:\/\/doi.org\/10.1182\/bloodadvances.2020003820.","journal-title":"Blood Adv"},{"issue":"5","key":"1713_CR67","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3390\/cancers12051065","volume":"12","author":"D Fassmannov\u00e1","year":"2020","unstructured":"Fassmannov\u00e1 D, Sedl\u00e1k F, Sedl\u00e1\u010dek J, et al. Nelfinavir inhibits the TCF11\/Nrf1-mediated proteasome recovery pathway in multiple myeloma. Cancers. 2020;12(5):1065. https:\/\/doi.org\/10.3390\/cancers12051065.","journal-title":"Cancers"},{"issue":"5","key":"1713_CR68","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41419-022-04925-3","volume":"13","author":"M Op","year":"2022","unstructured":"Op M, Ribeiro ST, Chavarria C, et al. The aspartyl protease DDI2 drives adaptation to proteasome inhibition in multiple myeloma. Cell Death Dis. 2022;13(5):475. https:\/\/doi.org\/10.1038\/s41419-022-04925-3.","journal-title":"Cell Death Dis"},{"issue":"2","key":"1713_CR69","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.molcel.2020.05.035","volume":"79","author":"AB Dirac-Svejstrup","year":"2020","unstructured":"Dirac-Svejstrup AB, Walker J, Faull P, et al. DDI2 is a ubiquitin-directed endoprotease responsible for cleavage of transcription factor NRF1. Mol Cell. 2020;79(2):332\u201341. https:\/\/doi.org\/10.1016\/j.molcel.2020.05.035.","journal-title":"Mol Cell"},{"key":"1713_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2020.109775","volume":"75","author":"Y Gu","year":"2020","unstructured":"Gu Y, Wang X, Wang Y, et al. Nelfinavir inhibits human DDI2 and potentiates cytotoxicity of proteasome inhibitors. Cell Signal. 2020;75: 109775. https:\/\/doi.org\/10.1016\/j.cellsig.2020.109775.","journal-title":"Cell Signal"},{"issue":"11","key":"1713_CR71","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1021\/acscentsci.7b00224","volume":"3","author":"FM Tomlin","year":"2017","unstructured":"Tomlin FM, Gerling-Driessen UIM, Liu YC, et al. Inhibition of NGLY1 inactivates the transcription factor Nrf1 and potentiates proteasome inhibitor cytotoxicity. ACS Cent Sci. 2017;3(11):1143\u201355. https:\/\/doi.org\/10.1021\/acscentsci.7b00224.","journal-title":"ACS Cent Sci"},{"issue":"1","key":"1713_CR72","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4161\/mabs.4.1.18347","volume":"4","author":"H Liu","year":"2012","unstructured":"Liu H, May K. Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function. MAbs. 2012;4(1):17\u201323. https:\/\/doi.org\/10.4161\/mabs.4.1.18347.","journal-title":"MAbs"},{"issue":"9","key":"1713_CR73","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1089\/ars.2009.2501","volume":"11","author":"Y Shimizu","year":"2009","unstructured":"Shimizu Y, Hendershot LM. Oxidative folding: cellular strategies for dealing with the resultant equimolar production of reactive oxygen species. Antioxid Redox Signal. 2009;11(9):2317\u201331. https:\/\/doi.org\/10.1089\/ars.2009.2501.","journal-title":"Antioxid Redox Signal"},{"issue":"19","key":"1713_CR74","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1016\/j.febslet.2007.04.031","volume":"581","author":"S Cenci","year":"2007","unstructured":"Cenci S, Sitia R. Managing and exploiting stress in the antibody factory. FEBS Lett. 2007;581(19):3652\u20137. https:\/\/doi.org\/10.1016\/j.febslet.2007.04.031.","journal-title":"FEBS Lett"},{"key":"1713_CR75","first-page":"261","volume-title":"Immunoglobulin assembly and secretion. Molecular Biology of B cells","author":"LM Hendershot","year":"2003","unstructured":"Hendershot LM, Sitia R. Immunoglobulin assembly and secretion. Molecular Biology of B cells. Elsevier Inc.; 2003. p. 261\u201373."},{"issue":"19","key":"1713_CR76","doi-asserted-by":"publisher","first-page":"20108","DOI":"10.1074\/jbc.M314219200","volume":"279","author":"SB Cullinan","year":"2004","unstructured":"Cullinan SB, Diehl JA. PERK-dependent activation of Nrf2 contributes to redox homeostasis and cell survival following endoplasmic reticulum stress. J Biol Chem. 2004;279(19):20108\u201317. https:\/\/doi.org\/10.1074\/jbc.M314219200.","journal-title":"J Biol Chem"},{"issue":"3","key":"1713_CR77","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/s1097-2765(03)00105-9","volume":"11","author":"HP Harding","year":"2003","unstructured":"Harding HP, Zhang Y, Zeng H, et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell. 2003;11(3):619\u201333. https:\/\/doi.org\/10.1016\/s1097-2765(03)00105-9.","journal-title":"Mol Cell"},{"issue":"3","key":"1713_CR78","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1089\/ars.2014.5851","volume":"21","author":"SS Cao","year":"2014","unstructured":"Cao SS, Kaufman RJ. Endoplasmic reticulum stress and oxidative stress in cell fate decision and human disease. Antioxid Redox Signal. 2014;21(3):396\u2013413. https:\/\/doi.org\/10.1089\/ars.2014.5851.","journal-title":"Antioxid Redox Signal"},{"issue":"17","key":"1713_CR79","doi-asserted-by":"publisher","first-page":"9946","DOI":"10.1073\/pnas.1334037100","volume":"100","author":"AH Lee","year":"2003","unstructured":"Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A. 2003;100(17):9946\u201351. https:\/\/doi.org\/10.1073\/pnas.1334037100.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"1713_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.56","volume":"6","author":"KK Starheim","year":"2016","unstructured":"Starheim KK, Holien T, Misund K, et al. Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells. Blood Cancer J. 2016;6(7): e446. https:\/\/doi.org\/10.1038\/bcj.2016.56.","journal-title":"Blood Cancer J"},{"issue":"9","key":"1713_CR81","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.3324\/haematol.2018.207704","volume":"104","author":"L Besse","year":"2019","unstructured":"Besse L, Besse A, Mendez-Lopez M, et al. (2019) A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis. Haematologica. 2019;104(9):e415\u20139. https:\/\/doi.org\/10.3324\/haematol.2018.207704.","journal-title":"Haematologica"},{"key":"1713_CR82","doi-asserted-by":"publisher","first-page":"5896","DOI":"10.1038\/srep05896","volume":"4","author":"S Maharjan","year":"2014","unstructured":"Maharjan S, Oku M, Tsuda M, et al. Mitochondrial impairment triggers cytosolic oxidative stress and cell death following proteasome inhibition. Sci Rep. 2014;4:5896. https:\/\/doi.org\/10.1038\/srep05896.","journal-title":"Sci Rep"},{"issue":"2","key":"1713_CR83","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/jcb.23387","volume":"113","author":"A Goel","year":"2012","unstructured":"Goel A, Spitz DR, Weiner GJ. Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma. J Cell Biochem. 2012;113(2):419\u201325. https:\/\/doi.org\/10.1002\/jcb.23387.","journal-title":"J Cell Biochem"},{"issue":"1","key":"1713_CR84","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1182\/blood-2005-05-2091","volume":"107","author":"P P\u00e9rez-Gal\u00e1n","year":"2006","unstructured":"P\u00e9rez-Gal\u00e1n P, Rou\u00e9 G, Villamor N, et al. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 2006;107(1):257\u201364. https:\/\/doi.org\/10.1182\/blood-2005-05-2091.","journal-title":"Blood"},{"issue":"36","key":"1713_CR85","doi-asserted-by":"publisher","first-page":"33714","DOI":"10.1074\/jbc.M302559200","volume":"278","author":"YH Ling","year":"2003","unstructured":"Ling YH, Liebes L, Zou Y, Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem. 2003;278(36):33714\u201323. https:\/\/doi.org\/10.1074\/jbc.M302559200.","journal-title":"J Biol Chem"},{"issue":"2","key":"1713_CR86","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/CAD.0b013e3282f24031","volume":"19","author":"D Llobet","year":"2008","unstructured":"Llobet D, Eritja N, Encinas M, et al. Antioxidants block proteasome inhibitor function in endometrial carcinoma cells. Anticancer Drugs. 2008;19(2):115\u201324. https:\/\/doi.org\/10.1097\/CAD.0b013e3282f24031.","journal-title":"Anticancer Drugs"},{"key":"1713_CR87","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/459052","volume":"2015","author":"L Gao","year":"2015","unstructured":"Gao L, Gao M, Yang G, et al. Synergistic activity of carfilzomib and panobinostat in multiple myeloma cells via modulation of ROS generation and ERK1\/2. Biomed Res Int. 2015;2015: 459052. https:\/\/doi.org\/10.1155\/2015\/459052.","journal-title":"Biomed Res Int"},{"issue":"21","key":"1713_CR88","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1158\/1078-0432.CCR-15-0530","volume":"21","author":"JP Laubach","year":"2015","unstructured":"Laubach JP, Moreau P, San-Miguel JF, Richardson PG. Panobinostat for the treatment of multiple myeloma. Clin Cancer Res. 2015;21(21):4767\u201373. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0530.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1713_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.406","volume":"4","author":"F Bruzzese","year":"2013","unstructured":"Bruzzese F, Pucci B, Milone MR, et al. Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways. Cell Death Dis. 2013;4(10): e878. https:\/\/doi.org\/10.1038\/cddis.2013.406.","journal-title":"Cell Death Dis"},{"issue":"11","key":"1713_CR90","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1158\/1078-0432.CCR-03-0561","volume":"10","author":"XY Pei","year":"2004","unstructured":"Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res. 2004;10(11):3839\u201352. https:\/\/doi.org\/10.1158\/1078-0432.CCR-03-0561.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1713_CR91","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccell.2018.03.022","volume":"34","author":"M Rojo de la Vega","year":"2018","unstructured":"Rojo de la Vega M, Chapman E, Zhang DD. NRF2 and the hallmarks of cancer. Cancer Cell. 2018;34(1):21\u201343. https:\/\/doi.org\/10.1016\/j.ccell.2018.03.022.","journal-title":"Cancer Cell"},{"issue":"11","key":"1713_CR92","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.3390\/ijms19113503","volume":"19","author":"CH Yen","year":"2018","unstructured":"Yen CH, Hsiao HH. NRF2 is one of the players involved in bone marrow mediated drug resistance in multiple myeloma. Int J Mol Sci. 2018;19(11):3503. https:\/\/doi.org\/10.3390\/ijms19113503.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1713_CR93","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/1535-7163.MCT-12-1151","volume":"12","author":"HA Stessman","year":"2013","unstructured":"Stessman HA, Baughn LB, Sarver A, et al. Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. Mol Cancer Ther. 2013;12(6):1140\u201350. https:\/\/doi.org\/10.1158\/1535-7163.MCT-12-1151.","journal-title":"Mol Cancer Ther"},{"issue":"Pt B","key":"1713_CR94","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.freeradbiomed.2015.06.014","volume":"88","author":"T Jiang","year":"2015","unstructured":"Jiang T, Harder B, Rojo de la Vega M, et al. p62 links autophagy and Nrf2 signaling. Free Radic Biol Med. 2015;88(Pt B):199\u2013204. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2015.06.014.","journal-title":"Free Radic Biol Med"},{"issue":"6","key":"1713_CR95","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.freeradbiomed.2015.06.014","volume":"83","author":"S Ruiz","year":"2013","unstructured":"Ruiz S, Pergola PE, Zager RA, Vaziri ND. Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int. 2013;83(6):199\u2013204. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2015.06.014.","journal-title":"Kidney Int"},{"issue":"15","key":"1713_CR96","doi-asserted-by":"publisher","first-page":"5101","DOI":"10.1158\/1078-0432.CCR-10-3367","volume":"17","author":"MA Weniger","year":"2011","unstructured":"Weniger MA, Rizzatti EG, P\u00e9rez-Gal\u00e1n P, et al. Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma. Clin Cancer Res. 2011;17(15):5101\u201312. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-3367.","journal-title":"Clin Cancer Res"},{"issue":"41","key":"1713_CR97","doi-asserted-by":"publisher","first-page":"66360","DOI":"10.18632\/oncotarget.11960","volume":"7","author":"I Riz","year":"2016","unstructured":"Riz I, Hawley TS, Marsal JW, Hawley RG. Noncanonical SQSTM1\/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming. Oncotarget. 2016;7(41):66360\u201385. https:\/\/doi.org\/10.18632\/oncotarget.11960.","journal-title":"Oncotarget"},{"issue":"13","key":"1713_CR98","doi-asserted-by":"publisher","first-page":"10021","DOI":"10.1074\/jbc.M111.277145","volume":"287","author":"AM Pickering","year":"2012","unstructured":"Pickering AM, Linder RA, Zhang H, et al. Nrf2-dependent induction of proteasome and Pa28\u03b1\u03b2 regulator are required for adaptation to oxidative stress. J Biol Chem. 2012;287(13):10021\u201331. https:\/\/doi.org\/10.1074\/jbc.M111.277145.","journal-title":"J Biol Chem"},{"issue":"50","key":"1713_CR99","doi-asserted-by":"publisher","first-page":"29854","DOI":"10.1074\/jbc.M115.664953","volume":"290","author":"B Li","year":"2015","unstructured":"Li B, Fu J, Chen P, et al. The nuclear factor (Erythroid-derived 2)-like 2 and proteasome maturation protein axis mediate bortezomib resistance in multiple myeloma. J Biol Chem. 2015;290(50):29854\u201368. https:\/\/doi.org\/10.1074\/jbc.M115.664953.","journal-title":"J Biol Chem"},{"key":"1713_CR100","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.canlet.2017.10.005","volume":"412","author":"Y Sun","year":"2018","unstructured":"Sun Y, Abdul Aziz A, Bowles K, Rushworth S. High NRF2 expression controls endoplasmic reticulum stress induced apoptosis in multiple myeloma. Cancer Lett. 2018;412:37\u201345. https:\/\/doi.org\/10.1016\/j.canlet.2017.10.005.","journal-title":"Cancer Lett"},{"issue":"18","key":"1713_CR101","doi-asserted-by":"publisher","first-page":"6723","DOI":"10.3390\/ijms21186723","volume":"21","author":"CH Yen","year":"2020","unstructured":"Yen CH, Hsu CM, Hsiao SY, Hsiao HH. Pathogenic mechanisms of myeloma bone disease and possible roles for NRF2. Int J Mol Sci. 2020;21(18):6723. https:\/\/doi.org\/10.3390\/ijms21186723.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"1713_CR102","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/bjc.2017.317","volume":"117","author":"F Chen","year":"2017","unstructured":"Chen F, Wang H, Zhu J, et al. Camptothecin suppresses NRF2-ARE activity and sensitises hepatocellular carcinoma cells to anticancer drugs. Br J Cancer. 2017;117(10):1495\u2013506. https:\/\/doi.org\/10.1038\/bjc.2017.317.","journal-title":"Br J Cancer"},{"issue":"11","key":"1713_CR103","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1021\/acschembio.6b00651","volume":"11","author":"A Singh","year":"2016","unstructured":"Singh A, Venkannagari S, Oh KH, et al. Small molecule inhibitor of NRF2 selectively intervenes therapeutic resistance in KEAP1-deficient NSCLC tumors. ACS Chem Biol. 2016;11(11):3214\u201325. https:\/\/doi.org\/10.1021\/acschembio.6b00651.","journal-title":"ACS Chem Biol"},{"issue":"2","key":"1713_CR104","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1089\/ars.2016.6841","volume":"27","author":"JL Roh","year":"2017","unstructured":"Roh JL, Jang H, Kim EH, Shin D. Targeting of the glutathione, thioredoxin, and Nrf2 antioxidant systems in head and neck cancer. Antioxid Redox Signal. 2017;27(2):106\u201314. https:\/\/doi.org\/10.1089\/ars.2016.6841.","journal-title":"Antioxid Redox Signal"},{"issue":"2","key":"1713_CR105","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3109\/03602532.2011.552912","volume":"43","author":"KD Tew","year":"2011","unstructured":"Tew KD, Townsend DM. Regulatory functions of glutathione S-transferase P1\u20131 unrelated to detoxification. Drug Metab Rev. 2011;43(2):179\u201393. https:\/\/doi.org\/10.3109\/03602532.2011.552912.","journal-title":"Drug Metab Rev"},{"issue":"1","key":"1713_CR106","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.cbpa.2010.10.016","volume":"15","author":"KD Tew","year":"2011","unstructured":"Tew KD, Townsend DM. Redox platforms in cancer drug discovery and development. Curr Opin Chem Biol. 2011;15(1):156\u201361. https:\/\/doi.org\/10.1016\/j.cbpa.2010.10.016.","journal-title":"Curr Opin Chem Biol"},{"issue":"4","key":"1713_CR107","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/j.1365-2141.2008.07066.x","volume":"141","author":"S Nerini-Molteni","year":"2008","unstructured":"Nerini-Molteni S, Ferrarini M, Cozza S, et al. Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib. Br J Haematol. 2008;141(4):494\u2013503. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07066.x.","journal-title":"Br J Haematol"},{"issue":"2","key":"1713_CR108","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1182\/blood-2006-10-052845","volume":"110","author":"T Kiziltepe","year":"2007","unstructured":"Kiziltepe T, Hideshima T, Ishitsuka K, et al. JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. Blood. 2007;110(2):709\u201318. https:\/\/doi.org\/10.1182\/blood-2006-10-052845.","journal-title":"Blood"},{"issue":"1","key":"1713_CR109","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1128\/CMR.12.1.19","volume":"12","author":"U Z\u00fcgel","year":"1999","unstructured":"Z\u00fcgel U, Kaufmann SH. Role of heat shock proteins in protection from and pathogenesis of infectious diseases. Clin Microbiol Rev. 1999;12(1):19\u201339. https:\/\/doi.org\/10.1128\/CMR.12.1.19.","journal-title":"Clin Microbiol Rev"},{"issue":"37","key":"1713_CR110","doi-asserted-by":"publisher","first-page":"59727","DOI":"10.18632\/oncotarget.10847","volume":"7","author":"SP Shah","year":"2016","unstructured":"Shah SP, Nooka AK, Jaye DL, et al. Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation. Oncotarget. 2016;7(37):59727\u201341. https:\/\/doi.org\/10.18632\/oncotarget.10847.","journal-title":"Oncotarget"},{"issue":"1","key":"1713_CR111","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.tcb.2015.10.011","volume":"26","author":"C Dai","year":"2016","unstructured":"Dai C, Sampson SB. HSF1: Guardian of Proteostasis in Cancer. Trends Cell Biol. 2016;26(1):17\u201328. https:\/\/doi.org\/10.1016\/j.tcb.2015.10.011.","journal-title":"Trends Cell Biol"},{"key":"1713_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molcel.2016.06.026","volume":"63","author":"CG Triandafillou","year":"2016","unstructured":"Triandafillou CG, Drummond DA. Heat shock factor 1: From fire chief to crowd-control specialist. Mol Cell. 2016;63:1\u20132. https:\/\/doi.org\/10.1016\/j.molcel.2016.06.026.","journal-title":"Mol Cell"},{"key":"1713_CR113","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.18632\/oncotarget.1584","volume":"5","author":"L Zhang","year":"2014","unstructured":"Zhang L, Fok JH, Davies FE. Heat shock proteins in multiple myeloma. Oncotarget. 2014;5:1132\u201348. https:\/\/doi.org\/10.18632\/oncotarget.1584.","journal-title":"Oncotarget"},{"issue":"2","key":"1713_CR114","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s12192-020-01078-0","volume":"25","author":"L Huang","year":"2020","unstructured":"Huang L, Wang Y, Bai J, et al. Blockade of HSP70 by VER-155008 synergistically enhances bortezomib-induced cytotoxicity in multiple myeloma. Cell Stress Chaperones. 2020;25(2):357\u201367. https:\/\/doi.org\/10.1007\/s12192-020-01078-0.","journal-title":"Cell Stress Chaperones"},{"issue":"13","key":"1713_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111428","volume":"40","author":"M Oro\u0144","year":"2022","unstructured":"Oro\u0144 M, Grochowski M, Jaiswar A, et al. The molecular network of the proteasome machinery inhibition response is orchestrated by HSP70, revealing vulnerabilities in cancer cells. Cell Rep. 2022;40(13): 111428. https:\/\/doi.org\/10.1016\/j.celrep.2022.111428.","journal-title":"Cell Rep"},{"issue":"11","key":"1713_CR116","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.3390\/molecules23112757","volume":"23","author":"C Sharma","year":"2018","unstructured":"Sharma C, Seo YH. Small molecule inhibitors of HSF1-activated pathways as potential next-generation anticancer therapeutics. Molecules. 2018;23(11):2757. https:\/\/doi.org\/10.3390\/molecules23112757.","journal-title":"Molecules"},{"issue":"10","key":"1713_CR117","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1158\/1078-0432.CCR-17-1594","volume":"24","author":"JHL Fok","year":"2018","unstructured":"Fok JHL, Hedayat S, Zhang L, et al. HSF1 is essential for myeloma cell survival and a promising therapeutic target. Clin Cancer Res. 2018;24(10):2395\u2013407. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1594.","journal-title":"Clin Cancer Res"},{"issue":"1738","key":"1713_CR118","doi-asserted-by":"publisher","first-page":"20160521","DOI":"10.1098\/rstb.2016.0521","volume":"373","author":"AL Edkins","year":"2018","unstructured":"Edkins AL, Price JT, Pockley AG, Blatch GL. Heat shock proteins as modulators and therapeutic targets of chronic disease: an integrated perspective. Philos Trans R Soc Lond B Biol Sci. 2018;373(1738):20160521. https:\/\/doi.org\/10.1098\/rstb.2016.0521.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"1713_CR119","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1083\/jcb.137.4.825","volume":"137","author":"FA Agarraberes","year":"1997","unstructured":"Agarraberes FA, Terlecky SR, Dice JF. An intralysosomal hsp70 is required for a selective pathway of lysosomal protein degradation. J Cell Biol. 1997;137:825\u201334. https:\/\/doi.org\/10.1083\/jcb.137.4.825.","journal-title":"J Cell Biol"},{"issue":"6","key":"1713_CR120","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41580-018-0001-6","volume":"19","author":"S Kaushik","year":"2018","unstructured":"Kaushik S, Cuervo AM. The coming of age of chaperone-mediated autophagy. Nat Rev Mol Cell Biol. 2018;19(6):365\u201381. https:\/\/doi.org\/10.1038\/s41580-018-0001-6.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1713_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2021.100400","volume":"28","author":"T Lacey","year":"2021","unstructured":"Lacey T, Lacey H. Linking hsp90\u2019s role as an evolutionary capacitator to the development of cancer. Cancer Treat Res Commun. 2021;28: 100400. https:\/\/doi.org\/10.1016\/j.ctarc.2021.100400.","journal-title":"Cancer Treat Res Commun"},{"key":"1713_CR122","doi-asserted-by":"publisher","first-page":"e358","DOI":"10.1016\/S1470-2045(13)70169-4","volume":"14","author":"R Garcia-carbonero","year":"2013","unstructured":"Garcia-carbonero R, Carnero A, Paz-ares L. Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol. 2013;14:e358\u201369. https:\/\/doi.org\/10.1016\/S1470-2045(13)70169-4.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1713_CR123","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.molcel.2019.03.032","volume":"74","author":"M Boysen","year":"2019","unstructured":"Boysen M, Kityk R, Mayer MP. Hsp70- and Hsp90-mediated regulation of the conformation of p53 DNA binding domain and p53 cancer variants. Mol Cell. 2019;74(4):831-843.e4. https:\/\/doi.org\/10.1016\/j.molcel.2019.03.032.","journal-title":"Mol Cell"},{"key":"1713_CR124","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.3324\/haematol.2012.066175","volume":"98","author":"M Chatterjee","year":"2013","unstructured":"Chatterjee M, Andrulis M, St\u00fchmer T, et al. The PI3K\/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma. Haematologica. 2013;98:1132\u201341. https:\/\/doi.org\/10.3324\/haematol.2012.066175.","journal-title":"Haematologica"},{"key":"1713_CR125","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/232037","volume":"2011","author":"MJ Braunstein","year":"2011","unstructured":"Braunstein MJ, Scott SS, Scott CM, et al. Antimyeloma effects of the heat shock protein 70 molecular chaperone inhibitor MAL3-101. J Oncol. 2011;2011: 232037. https:\/\/doi.org\/10.1155\/2011\/232037.","journal-title":"J Oncol"},{"key":"1713_CR126","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1158\/1535-7163.551.3.5","volume":"3","author":"EG Mimnaugh","year":"2004","unstructured":"Mimnaugh EG, Xu W, Vos M, et al. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther. 2004;3:551\u201366.","journal-title":"Mol Cancer Ther"},{"key":"1713_CR127","doi-asserted-by":"publisher","first-page":"17408","DOI":"10.1073\/pnas.0608372103","volume":"103","author":"JR Sydor","year":"2006","unstructured":"Sydor JR, Normant E, Pien CS, et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci U S A. 2006;103:17408\u201313. https:\/\/doi.org\/10.1073\/pnas.0608372103.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"1713_CR128","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2012.13","volume":"2","author":"T Ishii","year":"2012","unstructured":"Ishii T, Seike T, Nakashima T, et al. Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib. Blood Cancer J. 2012;2(4): e68. https:\/\/doi.org\/10.1038\/bcj.2012.13.","journal-title":"Blood Cancer J"},{"key":"1713_CR129","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/j.1600-0609.2012.01764.x","volume":"88","author":"B Lamottke","year":"2012","unstructured":"Lamottke B, Kaiser M, Mieth M, et al. The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases. Eur J Haematol. 2012;88:406\u201315. https:\/\/doi.org\/10.1111\/j.1600-0609.2012.01764.x.","journal-title":"Eur J Haematol"},{"key":"1713_CR130","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1038\/leu.2008.111","volume":"22","author":"T St\u00fchmer","year":"2008","unstructured":"St\u00fchmer T, Z\u00f6llinger A, Siegmund D, et al. Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia. 2008;22:1604\u201312. https:\/\/doi.org\/10.1038\/leu.2008.111.","journal-title":"Leukemia"},{"key":"1713_CR131","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1756-8722-3-40","volume":"3","author":"SZ Usmani","year":"2010","unstructured":"Usmani SZ, Bona RD, Chiosis G, Li Z. The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1. J Hematol Oncol. 2010;3:40. https:\/\/doi.org\/10.1186\/1756-8722-3-40.","journal-title":"J Hematol Oncol"},{"key":"1713_CR132","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1080\/15384047.2015.1071743","volume":"16","author":"CK Bailey","year":"2015","unstructured":"Bailey CK, Budina-Kolomets A, Murphy ME, Nefedova Y. Efficacy of the HSP70 inhibitor PET-16 in multiple myeloma. Cancer Biol Ther. 2015;16:1422\u20136. https:\/\/doi.org\/10.1080\/15384047.2015.1071743.","journal-title":"Cancer Biol Ther"},{"key":"1713_CR133","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1002\/cncr.29339","volume":"121","author":"R Seggewiss-Bernhardt","year":"2015","unstructured":"Seggewiss-Bernhardt R, Bargou RC, Goh YT, et al. Phase 1\/1B trial of the heat shock protein 90 inhibitor NVP- AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma. Cancer. 2015;121:2185\u201392. https:\/\/doi.org\/10.1002\/cncr.29339.","journal-title":"Cancer"},{"key":"1713_CR134","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/j.1365-2141.2010.08265.x","volume":"150","author":"PG Richardson","year":"2010","unstructured":"Richardson PG, Chanan-Khan AA, Alsina M, et al. Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study. Br J Haematol. 2010;150:438\u201345. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08265.x.","journal-title":"Br J Haematol"},{"key":"1713_CR135","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.3109\/10428194.2011.600481","volume":"52","author":"D Siegel","year":"2011","unstructured":"Siegel D, Jagannath S, Vesole DH, et al. A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. Leuk Lymphoma. 2011;52:2308\u201315. https:\/\/doi.org\/10.3109\/10428194.2011.600481.","journal-title":"Leuk Lymphoma"},{"key":"1713_CR136","doi-asserted-by":"publisher","first-page":"7896","DOI":"10.1158\/0008-5472.CAN-05-0506","volume":"65","author":"M Altun","year":"2005","unstructured":"Altun M, Galardy PJ, Shringarpure R, et al. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. Cancer Res. 2005;65:7896\u2013901. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-0506.","journal-title":"Cancer Res"},{"key":"1713_CR137","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/CE.S13838","volume":"6","author":"S Jain","year":"2011","unstructured":"Jain S, Diefenbach C, Zain J, O\u2019Connor OA. Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma. Core Evid. 2011;6:43\u201357. https:\/\/doi.org\/10.2147\/CE.S13838.","journal-title":"Core Evid"},{"key":"1713_CR138","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1182\/blood-2007-12-130823","volume":"112","author":"ST Nawrocki","year":"2008","unstructured":"Nawrocki ST, Carew JS, Maclean KH, et al. Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood. 2008;112:2917\u201326. https:\/\/doi.org\/10.1182\/blood-2007-12-130823.","journal-title":"Blood"},{"key":"1713_CR139","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.canlet.2013.07.023","volume":"339","author":"L Zhang","year":"2013","unstructured":"Zhang L, Fok JJ, Mirabella F, et al. Hsp70 inhibition induces myeloma cell death via the intracellular accumulation of immunoglobulin and the generation of proteotoxic stress. Cancer Lett. 2013;339:49\u201359. https:\/\/doi.org\/10.1016\/j.canlet.2013.07.023.","journal-title":"Cancer Lett"},{"issue":"8","key":"1713_CR140","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.chembiol.2022.06.010","volume":"29","author":"ID Ferguson","year":"2022","unstructured":"Ferguson ID, Lin YT, Lam C, et al. Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma. Cell Chem Biol. 2022;29(8):1288-1302.e7. https:\/\/doi.org\/10.1016\/j.chembiol.2022.06.010.","journal-title":"Cell Chem Biol"},{"issue":"16","key":"1713_CR141","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1056\/NEJMra2022774","volume":"383","author":"N Mizushima","year":"2020","unstructured":"Mizushima N, Levine B. Autophagy in human diseases. N Engl J Med. 2020;383(16):1564\u201376. https:\/\/doi.org\/10.1056\/NEJMra2022774.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"1713_CR142","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s10875-016-0254-9","volume":"36","author":"E Milan","year":"2016","unstructured":"Milan E, Fabbri M, Cenci S. Autophagy in plasma cell ontogeny and malignancy. J Clin Immunol. 2016;36(Suppl 1):18\u201324. https:\/\/doi.org\/10.1007\/s10875-016-0254-9.","journal-title":"J Clin Immunol"},{"issue":"4","key":"1713_CR143","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3324\/haematol.2014.116269","volume":"100","author":"A G\u00fcnther","year":"2015","unstructured":"G\u00fcnther A, Baumann P, Burger R, et al. Activity of everolimus (RAD001) in relapsed and\/or refractory multiple myeloma: a phase I study. Haematologica. 2015;100(4):541\u20137. https:\/\/doi.org\/10.3324\/haematol.2014.116269.","journal-title":"Haematologica"},{"key":"1713_CR144","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/bjh.12909","volume":"166","author":"AJ Yee","year":"2014","unstructured":"Yee AJ, Hari P, Marcheselli R, et al. Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. Br J Haematol. 2014;166:401\u20139. https:\/\/doi.org\/10.1111\/bjh.12909.","journal-title":"Br J Haematol"},{"key":"1713_CR145","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2353\/ajpath.2007.070188","volume":"171","author":"WX Ding","year":"2007","unstructured":"Ding WX, Ni HM, Gao W, et al. Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. Am J Pathol. 2007;171:513\u201324. https:\/\/doi.org\/10.2353\/ajpath.2007.070188.","journal-title":"Am J Pathol"},{"key":"1713_CR146","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/sj.cdd.4401984","volume":"14","author":"Y Kouroku","year":"2007","unstructured":"Kouroku Y, Fujita E, Tanida I, et al. ER stress (PERK\/eIF2alpha phosphorylation) mediates the polyglutamine-induced LC3 conversion, an essential step for autophagy formation. Cell Death Differ. 2007;14:230\u20139. https:\/\/doi.org\/10.1038\/sj.cdd.4401984.","journal-title":"Cell Death Differ"},{"key":"1713_CR147","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1158\/1535-7163.MCT-08-1177","volume":"8","author":"B Hoang","year":"2009","unstructured":"Hoang B, Benavides A, Shi Y, et al. Effect of autophagy on multiple myeloma cell viability. Mol Cancer Ther. 2009;8:1974\u201384. https:\/\/doi.org\/10.1158\/1535-7163.MCT-08-1177.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"1713_CR148","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.cell.2017.03.035","volume":"169","author":"RA Saxton","year":"2017","unstructured":"Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;169(2):361\u201371. https:\/\/doi.org\/10.1016\/j.cell.2017.03.035.","journal-title":"Cell"},{"issue":"7","key":"1713_CR149","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1080\/15548627.2015.1052928","volume":"11","author":"E Milan","year":"2015","unstructured":"Milan E, Perini T, Resnati M, et al. A plastic SQSTM1\/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells. Autophagy. 2015;11(7):1161\u201378. https:\/\/doi.org\/10.1080\/15548627.2015.1052928.","journal-title":"Autophagy"},{"issue":"5","key":"1713_CR150","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1083\/jcb.201708168","volume":"217","author":"Z Sha","year":"2018","unstructured":"Sha Z, Schnell HM, Ruoff K, Goldberg A. Rapid induction of p62 and GABARAPL1 upon proteasome inhibition promotes survival before autophagy activation. J Cell Biol. 2018;217(5):1757\u201376. https:\/\/doi.org\/10.1083\/jcb.201708168.","journal-title":"J Cell Biol"},{"issue":"1","key":"1713_CR151","doi-asserted-by":"publisher","first-page":"14405","DOI":"10.1038\/s41598-023-41492-9","volume":"13","author":"A Hatanaka","year":"2023","unstructured":"Hatanaka A, Nakada S, Matsumoto G, et al. The transcription factor NRF1 (NFE2L1) activates aggrephagy by inducing p62 and GABARAPL1 after proteasome inhibition to maintain proteostasis. Sci Rep. 2023;13(1):14405. https:\/\/doi.org\/10.1038\/s41598-023-41492-9.","journal-title":"Sci Rep"},{"issue":"6","key":"1713_CR152","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.202306150","volume":"223","author":"MA Ward","year":"2024","unstructured":"Ward MA, Vangala JR, Kamber Kaya HE, et al. Transcription factor Nrf1 regulates proteotoxic stress-induced autophagy. J Cell Biol. 2024;223(6): e202306150. https:\/\/doi.org\/10.1083\/jcb.202306150.","journal-title":"J Cell Biol"},{"issue":"12","key":"1713_CR153","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.7150\/thno.15584","volume":"6","author":"M Roy","year":"2016","unstructured":"Roy M, Liang L, Xiao X, et al. Lycorine downregulates HMGB1 to inhibit autophagy and enhances bortezomib activity in multiple myeloma. Theranostics. 2016;6(12):2209\u201324. https:\/\/doi.org\/10.7150\/thno.15584.","journal-title":"Theranostics"},{"key":"1713_CR154","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104961","volume":"100","author":"P Tang","year":"2024","unstructured":"Tang P, Yu Z, Sun H, et al. CRIP1 involves the pathogenesis of multiple myeloma via dual-regulation of proteasome and autophagy. EBioMedicine. 2024;100: 104961. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104961.","journal-title":"EBioMedicine"},{"issue":"9","key":"1713_CR155","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1111\/cas.13711","volume":"109","author":"Y Lu","year":"2018","unstructured":"Lu Y, Wang Y, Xu H, et al. Profilin 1 induces drug resistance through Beclin1 complex-mediated autophagy in multiple myeloma. Cancer Sci. 2018;109(9):2706\u201316. https:\/\/doi.org\/10.1111\/cas.13711.","journal-title":"Cancer Sci"},{"issue":"8","key":"1713_CR156","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.4161\/auto.29264","volume":"10","author":"DT Vogl","year":"2014","unstructured":"Vogl DT, Stadtmauer EA, Tan KS, et al. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed\/refractory myeloma. Autophagy. 2014;10(8):1380\u201390. https:\/\/doi.org\/10.4161\/auto.29264.","journal-title":"Autophagy"},{"issue":"43","key":"1713_CR157","doi-asserted-by":"publisher","first-page":"70845","DOI":"10.18632\/oncotarget.12226","volume":"7","author":"K Baranowska","year":"2016","unstructured":"Baranowska K, Misund K, Starheim KK, et al. Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells. Oncotarget. 2016;7(43):70845\u201356. https:\/\/doi.org\/10.18632\/oncotarget.12226.","journal-title":"Oncotarget"},{"issue":"3","key":"1713_CR158","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3892\/ijo.2010.882","volume":"38","author":"T Kawaguchi","year":"2011","unstructured":"Kawaguchi T, Miyazawa K, Moriya S, et al. Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress. Int J Oncol. 2011;38(3):643\u201354. https:\/\/doi.org\/10.3892\/ijo.2010.882.","journal-title":"Int J Oncol"},{"issue":"1","key":"1713_CR159","doi-asserted-by":"publisher","first-page":"644","DOI":"10.3390\/ijms24010644","volume":"24","author":"OS Al-Odat","year":"2022","unstructured":"Al-Odat OS, Guirguis DA, Schmalbach NK, et al. Autophagy and apoptosis: current challenges of treatment and drug resistance in multiple myeloma. Int J Mol Sci. 2022;24(1):644. https:\/\/doi.org\/10.3390\/ijms24010644.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1713_CR160","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrm3270","volume":"13","author":"C Hetz","year":"2012","unstructured":"Hetz C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol. 2012;13(2):89\u2013102. https:\/\/doi.org\/10.1038\/nrm3270.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"1713_CR161","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3390\/biology10050384","volume":"10","author":"A Read","year":"2021","unstructured":"Read A, Schr\u00f6der M. The unfolded protein response: an overview. Biology. 2021;10(5):384. https:\/\/doi.org\/10.3390\/biology10050384.","journal-title":"Biology"},{"issue":"1","key":"1713_CR162","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/med.21921","volume":"43","author":"A Ajoolabady","year":"2023","unstructured":"Ajoolabady A, Lebeaupin C, Wu NN, et al. ER stress and inflammation crosstalk in obesity. Med Res Rev. 2023;43(1):5\u201330. https:\/\/doi.org\/10.1002\/med.21921.","journal-title":"Med Res Rev"},{"issue":"1\u20132","key":"1713_CR163","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.mrfmmm.2004.06.056","volume":"569","author":"M Schr\u00f6der","year":"2005","unstructured":"Schr\u00f6der M, Kaufman RJ. ER stress and the unfolded protein response. Mutat Res. 2005;569(1\u20132):29\u201363. https:\/\/doi.org\/10.1016\/j.mrfmmm.2004.06.056.","journal-title":"Mutat Res"},{"issue":"10","key":"1713_CR164","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1172\/JCI26373","volume":"115","author":"C Xu","year":"2005","unstructured":"Xu C, Bailly-Maitre B, Reed JC. Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest. 2005;115(10):2656\u201364. https:\/\/doi.org\/10.1172\/JCI26373.","journal-title":"J Clin Invest"},{"issue":"1","key":"1713_CR165","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/s41392-023-01570-w","volume":"8","author":"X Chen","year":"2023","unstructured":"Chen X, Shi C, He M, Xiong S, Xia X. Endoplasmic reticulum stress: molecular mechanism and therapeutic targets. Signal Transduct Target Ther. 2023;8(1):352. https:\/\/doi.org\/10.1038\/s41392-023-01570-w.","journal-title":"Signal Transduct Target Ther"},{"key":"1713_CR166","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1016\/j.bbamcr.2013.01.016","volume":"11","author":"J Hollien","year":"1833","unstructured":"Hollien J. (2013) Evolution of the unfolded protein response. Biochim Biophys Acta. 1833;11:2458\u201363. https:\/\/doi.org\/10.1016\/j.bbamcr.2013.01.016.","journal-title":"Biochim Biophys Acta"},{"issue":"7","key":"1713_CR167","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1182\/blood-2006-11-053728","volume":"110","author":"EL Davenport","year":"2007","unstructured":"Davenport EL, Moore HE, Dunlop AS, et al. Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood. 2007;110(7):2641\u20139. https:\/\/doi.org\/10.1182\/blood-2006-11-053728.","journal-title":"Blood"},{"issue":"1","key":"1713_CR168","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1007","volume":"7","author":"N Nikesitch","year":"2018","unstructured":"Nikesitch N, Lee JM, Ling S, Roberts TL. Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance. Clin Transl Immunol. 2018;7(1): e1007. https:\/\/doi.org\/10.1002\/cti2.1007.","journal-title":"Clin Transl Immunol"},{"issue":"6","key":"1713_CR169","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/35014014","volume":"2","author":"A Bertolotti","year":"2000","unstructured":"Bertolotti A, Zhang Y, Hendershot LM, et al. Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nat Cell Biol. 2000;2(6):326\u201332. https:\/\/doi.org\/10.1038\/35014014.","journal-title":"Nat Cell Biol"},{"issue":"5","key":"1713_CR170","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/s1097-2765(00)80330-5","volume":"5","author":"HP Harding","year":"2000","unstructured":"Harding HP, Zhang Y, Bertolotti A, et al. Perk is essential for translational regulation and cell survival during the unfolded protein response. Mol Cell. 2000;5(5):897\u2013904. https:\/\/doi.org\/10.1016\/s1097-2765(00)80330-5.","journal-title":"Mol Cell"},{"issue":"3","key":"1713_CR171","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.bbrc.2016.11.047","volume":"482","author":"DJ McConkey","year":"2017","unstructured":"McConkey DJ. The integrated stress response and proteotoxicity in cancer therapy. Biochem Biophys Res Commun. 2017;482(3):450\u20133. https:\/\/doi.org\/10.1016\/j.bbrc.2016.11.047.","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"1713_CR172","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.15252\/embr.201642195","volume":"17","author":"K Pakos-Zebrucka","year":"2016","unstructured":"Pakos-Zebrucka K, Koryga I, Mnich K, et al. The integrated stress response. EMBO Rep. 2016;17(10):1374\u201395. https:\/\/doi.org\/10.15252\/embr.201642195.","journal-title":"EMBO Rep"},{"key":"1713_CR173","doi-asserted-by":"publisher","first-page":"1112253","DOI":"10.3389\/fnmol.2023.1112253","volume":"16","author":"G Neill","year":"2023","unstructured":"Neill G, Masson GR. A stay of execution: ATF4 regulation and potential outcomes for the integrated stress response. Front Mol Neurosci. 2023;16:1112253. https:\/\/doi.org\/10.3389\/fnmol.2023.1112253.","journal-title":"Front Mol Neurosci"},{"issue":"9","key":"1713_CR174","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1158\/0008-5472.CAN-07-6215","volume":"68","author":"AC Ranganathan","year":"2008","unstructured":"Ranganathan AC, Ojha S, Kourtidis A, et al. Dual function of pancreatic endoplasmic reticulum kinase in tumor cell growth arrest and survival. Cancer Res. 2008;68(9):3260\u20138. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-6215.","journal-title":"Cancer Res"},{"issue":"7","key":"1713_CR175","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/j.ajpath.2016.03.004","volume":"186","author":"Y Ho","year":"2016","unstructured":"Ho Y, Li X, Jamison S, et al. PERK activation promotes medulloblastoma tumorigenesis by attenuating premalignant granule cell precursor apoptosis. Am J Pathol. 2016;186(7):1939\u201351. https:\/\/doi.org\/10.1016\/j.ajpath.2016.03.004.","journal-title":"Am J Pathol"},{"issue":"39","key":"1713_CR176","doi-asserted-by":"publisher","first-page":"64124","DOI":"10.18632\/oncotarget.11873","volume":"7","author":"S Stone","year":"2016","unstructured":"Stone S, Ho Y, Li X, et al. Dual role of the integrated stress response in medulloblastoma tumorigenesis. Oncotarget. 2016;7(39):64124\u201335. https:\/\/doi.org\/10.18632\/oncotarget.11873.","journal-title":"Oncotarget"},{"issue":"1","key":"1713_CR177","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.1038\/s41598-019-39547-x","volume":"9","author":"Z Shi","year":"2019","unstructured":"Shi Z, Yu X, Yuan M, et al. Activation of the PERK-ATF4 pathway promotes chemo-resistance in colon cancer cells. Sci Rep. 2019;9(1):3210. https:\/\/doi.org\/10.1038\/s41598-019-39547-x.","journal-title":"Sci Rep"},{"issue":"1","key":"1713_CR178","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12943-017-0657-0","volume":"16","author":"IC Salaroglio","year":"2017","unstructured":"Salaroglio IC, Panada E, Moiso E, et al. PERK induces resistance to cell death elicited by endoplasmic reticulum stress and chemotherapy. Mol Cancer. 2017;16(1):91. https:\/\/doi.org\/10.1186\/s12943-017-0657-0.","journal-title":"Mol Cancer"},{"issue":"3","key":"1713_CR179","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3390\/cancers11030338","volume":"11","author":"E Bahar","year":"2019","unstructured":"Bahar E, Kim JY, Yoon H. Chemotherapy resistance explained through endoplasmic reticulum stress-dependent signaling. Cancers. 2019;11(3):338. https:\/\/doi.org\/10.3390\/cancers11030338.","journal-title":"Cancers"},{"issue":"10","key":"1713_CR180","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.3390\/cancers12102864","volume":"12","author":"T Bagratuni","year":"2020","unstructured":"Bagratuni T, Patseas D, Mavrianou-Koutsoukou N, et al. Characterization of a PERK kinase inhibitor with anti-myeloma activity. Cancers. 2020;12(10):2864. https:\/\/doi.org\/10.3390\/cancers12102864.","journal-title":"Cancers"},{"issue":"23","key":"1713_CR181","doi-asserted-by":"publisher","first-page":"4870","DOI":"10.1158\/1078-0432.CCR-23-1182","volume":"29","author":"ME Stokes","year":"2023","unstructured":"Stokes ME, Calvo V, Fujisawa S, et al. PERK inhibition by HC-5404 sensitizes renal cell carcinoma tumor models to antiangiogenic tyrosine kinase inhibitors. Clin Cancer Res. 2023;29(23):4870\u201382. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1182.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1713_CR182","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1158\/0008-5472.CAN-08-3858","volume":"69","author":"DM Schewe","year":"2009","unstructured":"Schewe DM, Aguirre-Ghiso JA. Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy. Cancer Res. 2009;69(4):1545\u201352. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-3858.","journal-title":"Cancer Res"},{"issue":"10","key":"1713_CR183","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025820","volume":"6","author":"AS Michallet","year":"2011","unstructured":"Michallet AS, Mondiere P, Taillardet M, et al. Compromising the unfolded protein response induces autophagy-mediated cell death in multiple myeloma cells. PLoS ONE. 2011;6(10): e25820. https:\/\/doi.org\/10.1371\/journal.pone.0025820.","journal-title":"PLoS ONE"},{"issue":"2","key":"1713_CR184","doi-asserted-by":"publisher","first-page":"E117","DOI":"10.1073\/pnas.1514076113","volume":"113","author":"A De Gassart","year":"2016","unstructured":"De Gassart A, Bujisic B, Zaffalon L, et al. An inhibitor of HIV-1 protease modulates constitutive eIF2\u03b1 dephosphorylation to trigger a specific integrated stress response. Proc Natl Acad Sci U S A. 2016;113(2):E117\u201326. https:\/\/doi.org\/10.1073\/pnas.1514076113.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1713_CR185","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2022.104594","volume":"380","author":"TF Tang","year":"2022","unstructured":"Tang TF, Chan YT, Cheong HC, et al. Regulatory network of BLIMP1, IRF4, and XBP1 triad in plasmacytic differentiation and multiple myeloma pathogenesis. Cell Immunol. 2022;380: 104594. https:\/\/doi.org\/10.1016\/j.cellimm.2022.104594.","journal-title":"Cell Immunol"},{"key":"1713_CR186","doi-asserted-by":"publisher","first-page":"7448","DOI":"10.1128\/MCB.23.21.7448-7459.2003","volume":"23","author":"AH Lee","year":"2003","unstructured":"Lee AH, Iwakoshi NN, Glimcher LH. XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. Mol Cell Biol. 2003;23:7448\u201359. https:\/\/doi.org\/10.1128\/MCB.23.21.7448-7459.2003.","journal-title":"Mol Cell Biol"},{"issue":"24","key":"1713_CR187","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.1038\/sj.emboj.7600903","volume":"24","author":"AH Lee","year":"2005","unstructured":"Lee AH, Chu GC, Iwakoshi NN, Glimcher LH. XBP-1 is required for biogenesis of cellular secretory machinery of exocrine glands. EMBO J. 2005;24(24):4368\u201380. https:\/\/doi.org\/10.1038\/sj.emboj.7600903.","journal-title":"EMBO J"},{"issue":"2","key":"1713_CR188","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/aja.1001970207","volume":"197","author":"IM Clauss","year":"1993","unstructured":"Clauss IM, Gravallese EM, Darling JM, et al. In situ hybridization studies suggest a role for the basic region-leucine zipper protein hXBP-1 in exocrine gland and skeletal development during mouse embryogenesis. Dev Dyn. 1993;197(2):146\u201356. https:\/\/doi.org\/10.1002\/aja.1001970207.","journal-title":"Dev Dyn"},{"issue":"2","key":"1713_CR189","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1084\/jem.183.2.393","volume":"183","author":"AM Reimold","year":"1996","unstructured":"Reimold AM, Ponath PD, Li YS, et al. Transcription factor B cell lineage-specific activator protein regulates the gene for human X-box binding protein 1. J Exp Med. 1996;183(2):393\u2013401. https:\/\/doi.org\/10.1084\/jem.183.2.393.","journal-title":"J Exp Med"},{"issue":"6844","key":"1713_CR190","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/35085509","volume":"412","author":"AM Reimold","year":"2001","unstructured":"Reimold AM, Iwakoshi NN, Manis J, et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature. 2001;412(6844):300\u20137. https:\/\/doi.org\/10.1038\/35085509.","journal-title":"Nature"},{"issue":"7","key":"1713_CR191","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.4049\/jimmunol.1201042","volume":"189","author":"N Taubenheim","year":"2012","unstructured":"Taubenheim N, Tarlinton DM, Crawford S, et al. High rate of antibody secretion is not integral to plasma cell differentiation as revealed by XBP-1 deficiency. J Immunol. 2012;189(7):3328\u201338. https:\/\/doi.org\/10.4049\/jimmunol.1201042.","journal-title":"J Immunol"},{"issue":"10","key":"1713_CR192","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1084\/jem.20090738","volume":"206","author":"DJ Todd","year":"2009","unstructured":"Todd DJ, McHeyzer-Williams LJ, Kowal C, et al. XBP1 governs late events in plasma cell differentiation and is not required for antigen-specific memory B cell development. J Exp Med. 2009;206(10):2151\u20139. https:\/\/doi.org\/10.1084\/jem.20090738.","journal-title":"J Exp Med"},{"issue":"3","key":"1713_CR193","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/ni.3348","volume":"17","author":"J Tellier","year":"2016","unstructured":"Tellier J, Shi W, Minnich M, et al. Blimp-1 controls plasma cell function through the regulation of immunoglobulin secretion and the unfolded protein response. Nat Immunol. 2016;17(3):323\u201330. https:\/\/doi.org\/10.1038\/ni.3348.","journal-title":"Nat Immunol"},{"key":"1713_CR194","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.ccr.2007.02.015","volume":"11","author":"DR Carrasco","year":"2007","unstructured":"Carrasco DR, Sukhdeo K, Protopopova M, et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell. 2007;11:349\u201360. https:\/\/doi.org\/10.1016\/j.ccr.2007.02.015.","journal-title":"Cancer Cell"},{"issue":"5","key":"1713_CR195","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1182\/blood-2003-02-0402","volume":"103","author":"NC Munshi","year":"2004","unstructured":"Munshi NC, Hideshima T, Carrasco D, et al. Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood. 2004;103(5):1799\u2013806. https:\/\/doi.org\/10.1182\/blood-2003-02-0402.","journal-title":"Blood"},{"issue":"2","key":"1713_CR196","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1182\/blood-2010-01-263236","volume":"116","author":"T Bagratuni","year":"2010","unstructured":"Bagratuni T, Wu P, Gonzalez de Castro D, et al. XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. Blood. 2010;116(2):250\u20133. https:\/\/doi.org\/10.1182\/blood-2010-01-263236.","journal-title":"Blood"},{"issue":"7","key":"1713_CR197","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124698","volume":"4","author":"J Kellner","year":"2019","unstructured":"Kellner J, Wallace C, Liu B, Li Z. Definition of a multiple myeloma progenitor population in mice driven by enforced expression of XBP1s. JCI Insight. 2019;4(7): e124698. https:\/\/doi.org\/10.1172\/jci.insight.124698.","journal-title":"JCI Insight"},{"issue":"2","key":"1713_CR198","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1182\/blood-2010-02-269514","volume":"117","author":"P P\u00e9rez-Gal\u00e1n","year":"2011","unstructured":"P\u00e9rez-Gal\u00e1n P, Mora-Jensen H, Weniger MA, et al. Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood. 2011;117(2):542\u201352. https:\/\/doi.org\/10.1182\/blood-2010-02-269514.","journal-title":"Blood"},{"issue":"33","key":"1713_CR199","doi-asserted-by":"publisher","first-page":"16420","DOI":"10.1073\/pnas.1906999116","volume":"116","author":"JM Harnoss","year":"2019","unstructured":"Harnoss JM, Le Thomas A, Shemorry A, et al. Disruption of IRE1\u03b1 through its kinase domain attenuates multiple myeloma. Proc Natl Acad Sci U S A. 2019;116(33):16420\u20139. https:\/\/doi.org\/10.1073\/pnas.1906999116.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"1713_CR200","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41591-018-0269-2","volume":"24","author":"G Ledergor","year":"2018","unstructured":"Ledergor G, Weiner A, Zada M, et al. Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. Nat Med. 2018;24(12):1867\u201376. https:\/\/doi.org\/10.1038\/s41591-018-0269-2.","journal-title":"Nat Med"},{"issue":"4","key":"1713_CR201","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s12185-020-02829-6","volume":"111","author":"Y Furukawa","year":"2020","unstructured":"Furukawa Y, Kikuchi J. Molecular basis of clonal evolution in multiple myeloma. Int J Hematol. 2020;111(4):496\u2013511. https:\/\/doi.org\/10.1007\/s12185-020-02829-6.","journal-title":"Int J Hematol"},{"key":"1713_CR202","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.3389\/fonc.2019.01530","volume":"9","author":"B Borjan","year":"2020","unstructured":"Borjan B, Kern J, Steiner N, et al. Spliced XBP1 levels determine sensitivity of multiple myeloma cells to proteasome inhibitor bortezomib independent of the unfolded protein response mediator GRP78. Front Oncol. 2020;9:1530. https:\/\/doi.org\/10.3389\/fonc.2019.01530.","journal-title":"Front Oncol"},{"issue":"1","key":"1713_CR203","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fonc.2019.01530","volume":"97","author":"SC Ling","year":"2012","unstructured":"Ling SC, Lau EK, Al-Shabeeb A, et al. Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica. 2012;97(1):64\u201372. https:\/\/doi.org\/10.3389\/fonc.2019.01530.","journal-title":"Haematologica"},{"issue":"3","key":"1713_CR204","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41389-020-0216-1","volume":"9","author":"M Zang","year":"2020","unstructured":"Zang M, Guo J, Liu L, et al. Cdc37 suppression induces plasma cell immaturation and bortezomib resistance in multiple myeloma via Xbp1s. Oncogenesis. 2020;9(3):31. https:\/\/doi.org\/10.1038\/s41389-020-0216-1.","journal-title":"Oncogenesis"},{"issue":"11","key":"1713_CR205","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.3390\/cells10112853","volume":"10","author":"L Besse","year":"2021","unstructured":"Besse L, Besse A, Kraus M, et al. High immunoproteasome activity and sXBP1 in pediatric precursor B-ALL predicts sensitivity towards proteasome inhibitors. Cells. 2021;10(11):2853. https:\/\/doi.org\/10.3390\/cells10112853.","journal-title":"Cells"},{"issue":"2","key":"1713_CR206","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.3324\/haematol.2013.090142","volume":"99","author":"M Gambella","year":"2014","unstructured":"Gambella M, Rocci A, Passera R, et al. High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib. Haematologica. 2014;99(2):e14\u20136. https:\/\/doi.org\/10.3324\/haematol.2013.090142.","journal-title":"Haematologica"},{"issue":"5","key":"1713_CR207","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1182\/bloodadvances.2018019851","volume":"3","author":"XQ Qin","year":"2019","unstructured":"Qin XQ, An G, Li ZJ, et al. Secretory status of monoclonal immunoglobulin is related to the outcome of patients with myeloma: a retrospective study. Blood Adv. 2019;3(5):751\u201360. https:\/\/doi.org\/10.1182\/bloodadvances.2018019851.","journal-title":"Blood Adv"},{"issue":"6","key":"1713_CR208","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/bjh.12310","volume":"161","author":"SY Hong","year":"2013","unstructured":"Hong SY, Hagen T. Multiple myeloma Leu167Ile (c.499C>A) mutation prevents XBP1 mRNA splicing. Br J Haematol. 2013;161(6):898\u2013901. https:\/\/doi.org\/10.1111\/bjh.12310.","journal-title":"Br J Haematol"},{"issue":"7339","key":"1713_CR209","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature09837","volume":"471","author":"MA Chapman","year":"2011","unstructured":"Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471(7339):467\u201372. https:\/\/doi.org\/10.1038\/nature09837.","journal-title":"Nature"},{"issue":"1","key":"1713_CR210","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1080\/16078454.2022.2117123","volume":"27","author":"L Zhang","year":"2022","unstructured":"Zhang L, Gong J, Yaqiong L. Spliced X-Box binding protein 1 predicts satisfying responsiveness and survival benefit toward bortezomib-based therapy in multiple myeloma patients. Hematology. 2022;27(1):1102\u20139. https:\/\/doi.org\/10.1080\/16078454.2022.2117123.","journal-title":"Hematology"},{"issue":"6","key":"1713_CR211","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1002\/j.1460-2075.1990.tb08300.x","volume":"9","author":"JM Peters","year":"1990","unstructured":"Peters JM, Walsh MJ, Franke WW. An abundant and ubiquitous homo-oligomeric ring-shaped ATPase particle related to the putative vesicle fusion proteins Sec18p and NSF. EMBO J. 1990;9(6):1757\u201367. https:\/\/doi.org\/10.1002\/j.1460-2075.1990.tb08300.x.","journal-title":"EMBO J"},{"issue":"1","key":"1713_CR212","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.chembiol.2022.12.007","volume":"30","author":"S Kilgas","year":"2023","unstructured":"Kilgas S, Ramadan K. Inhibitors of the ATPase p97\/VCP: from basic research to clinical applications. Cell Chem Biol. 2023;30(1):3\u201321. https:\/\/doi.org\/10.1016\/j.chembiol.2022.12.007.","journal-title":"Cell Chem Biol"},{"issue":"6","key":"1713_CR213","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/0092-8674(95)90268-6","volume":"82","author":"M Latterich","year":"1995","unstructured":"Latterich M, Fr\u00f6hlich KU, Schekman R. Membrane fusion and the cell cycle: Cdc48p participates in the fusion of ER membranes. Cell. 1995;82(6):885\u201393. https:\/\/doi.org\/10.1016\/0092-8674(95)90268-6.","journal-title":"Cell"},{"issue":"6442","key":"1713_CR214","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/365176a0","volume":"365","author":"T Sommer","year":"1993","unstructured":"Sommer T, Jentsch S. A protein translocation defect linked to ubiquitin conjugation at the endoplasmic reticulum. Nature. 1993;365(6442):176\u20139. https:\/\/doi.org\/10.1038\/365176a0.","journal-title":"Nature"},{"issue":"4","key":"1713_CR215","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1152\/physrev.00041.2021","volume":"102","author":"MA Eldeeb","year":"2022","unstructured":"Eldeeb MA, Thomas RA, Ragheb MA, et al. Mitochondrial quality control in health and in Parkinson\u2019s disease. Physiol Rev. 2022;102(4):1721\u201355. https:\/\/doi.org\/10.1152\/physrev.00041.2021.","journal-title":"Physiol Rev"},{"issue":"2","key":"1713_CR216","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/cr.2011.80","volume":"22","author":"HN Ramanathan","year":"2012","unstructured":"Ramanathan HN, Ye Y. The p97 ATPase associates with EEA1 to regulate the size of early endosomes. Cell Res. 2012;22(2):346\u201359. https:\/\/doi.org\/10.1038\/cr.2011.80.","journal-title":"Cell Res"},{"key":"1713_CR217","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00308","volume":"2","author":"R Verma","year":"2013","unstructured":"Verma R, Oania RS, Kolawa NJ, Deshaies RJ. Cdc48\/p97 promotes degradation of aberrant nascent polypeptides bound to the ribosome. Elife. 2013;2: e00308. https:\/\/doi.org\/10.7554\/eLife.00308.","journal-title":"Elife"},{"issue":"19 Pt A","key":"1713_CR218","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1016\/j.febslet.2015.08.028","volume":"589","author":"A Buchberger","year":"2015","unstructured":"Buchberger A, Schindelin H, H\u00e4nzelmann P. Control of p97 function by cofactor binding. FEBS Lett. 2015;589(19 Pt A):2578\u201389. https:\/\/doi.org\/10.1016\/j.febslet.2015.08.028.","journal-title":"FEBS Lett"},{"issue":"6452","key":"1713_CR219","doi-asserted-by":"publisher","first-page":"eaax1033","DOI":"10.1126\/science.aax1033","volume":"365","author":"EC Twomey","year":"2019","unstructured":"Twomey EC, Ji Z, Wales TE, et al. Substrate processing by the Cdc48 ATPase complex is initiated by ubiquitin unfolding. Science. 2019;365(6452):eaax1033. https:\/\/doi.org\/10.1126\/science.aax1033.","journal-title":"Science"},{"issue":"5783","key":"1713_CR220","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.1129631","volume":"313","author":"J Hollien","year":"2006","unstructured":"Hollien J, Weissman JS. Decay of endoplasmic reticulum-localized mRNAs during the unfolded protein response. Science. 2006;313(5783):104\u20137. https:\/\/doi.org\/10.1126\/science.1129631.","journal-title":"Science"},{"key":"1713_CR221","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12915-014-0094-0","volume":"12","author":"RJ Deshaies","year":"2014","unstructured":"Deshaies RJ. Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy. BMC Biol. 2014;12:94. https:\/\/doi.org\/10.1186\/s12915-014-0094-0.","journal-title":"BMC Biol"},{"issue":"5","key":"1713_CR222","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.ccell.2015.10.002","volume":"28","author":"DJ Anderson","year":"2015","unstructured":"Anderson DJ, Le Moigne R, Djakovic S, et al. Targeting the AAA ATPase p97 as an approach to treat cancer through disruption of protein homeostasis. Cancer Cell. 2015;28(5):653\u201365. https:\/\/doi.org\/10.1016\/j.ccell.2015.10.002.","journal-title":"Cancer Cell"},{"issue":"10","key":"1713_CR223","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.2217\/fon.14.30","volume":"10","author":"Z Huang","year":"2014","unstructured":"Huang Z, Wu Y, Zhou X, et al. Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials. Future Oncol. 2014;10(10):1795\u2013807. https:\/\/doi.org\/10.2217\/fon.14.30.","journal-title":"Future Oncol"},{"issue":"9","key":"1713_CR224","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.4161\/auto.7.9.16489","volume":"7","author":"TF Chou","year":"2011","unstructured":"Chou TF, Deshaies RJ. Development of p97 AAA ATPase inhibitors. Autophagy. 2011;7(9):1091\u20132. https:\/\/doi.org\/10.4161\/auto.7.9.16489.","journal-title":"Autophagy"},{"issue":"4","key":"1713_CR225","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41589-020-00726-x","volume":"17","author":"SM Hill","year":"2021","unstructured":"Hill SM, Wrobel L, Ashkenazi A, et al. VCP\/p97 regulates Beclin-1-dependent autophagy initiation. Nat Chem Biol. 2021;17(4):448\u201355. https:\/\/doi.org\/10.1038\/s41589-020-00726-x.","journal-title":"Nat Chem Biol"},{"issue":"9","key":"1713_CR226","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074415","volume":"8","author":"HW Auner","year":"2013","unstructured":"Auner HW, Moody AM, Ward TH, et al. Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells. PLoS ONE. 2013;8(9): e74415. https:\/\/doi.org\/10.1371\/journal.pone.0074415.","journal-title":"PLoS ONE"},{"issue":"11","key":"1713_CR227","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1038\/leu.2016.102","volume":"30","author":"GP Soriano","year":"2016","unstructured":"Soriano GP, Besse L, Li N, et al. Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism. Leukemia. 2016;30(11):2198\u2013207. https:\/\/doi.org\/10.1038\/leu.2016.102.","journal-title":"Leukemia"},{"issue":"11","key":"1713_CR228","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1158\/1535-7163.MCT-17-0233","volume":"16","author":"R Le Moigne","year":"2017","unstructured":"Le Moigne R, Aftab BT, Djakovic S, et al. The p97 inhibitor CB-5083 is a unique disrupter of protein homeostasis in models of multiple myeloma. Mol Cancer Ther. 2017;16(11):2375\u201386. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0233.","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"1713_CR229","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1111\/cas.14154","volume":"110","author":"N Nishimura","year":"2019","unstructured":"Nishimura N, Radwan MO, Amano M, et al. Novel p97\/VCP inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib-sensitive and -resistant multiple myeloma cells. Cancer Sci. 2019;110(10):3275\u201387. https:\/\/doi.org\/10.1111\/cas.14154.","journal-title":"Cancer Sci"},{"issue":"7684","key":"1713_CR230","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/nature25016","volume":"552","author":"Z Skrott","year":"2017","unstructured":"Skrott Z, Mistrik M, Andersen KK, et al. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature. 2017;552(7684):194\u20139. https:\/\/doi.org\/10.1038\/nature25016.","journal-title":"Nature"},{"issue":"1","key":"1713_CR231","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41467-020-20359-x","volume":"12","author":"M Pan","year":"2021","unstructured":"Pan M, Zheng Q, Yu Y, et al. Seesaw conformations of Npl4 in the human p97 complex and the inhibitory mechanism of a disulfiram derivative. Nat Commun. 2021;12(1):121. https:\/\/doi.org\/10.1038\/s41467-020-20359-x.","journal-title":"Nat Commun"},{"issue":"3","key":"1713_CR232","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41419-022-04651-w","volume":"13","author":"K Chroma","year":"2022","unstructured":"Chroma K, Skrott Z, Gursky J, et al. A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment. Cell Death Dis. 2022;13(3):203. https:\/\/doi.org\/10.1038\/s41419-022-04651-w.","journal-title":"Cell Death Dis"},{"key":"1713_CR233","doi-asserted-by":"publisher","first-page":"RP87301","DOI":"10.7554\/eLife.87301","volume":"12","author":"S Tilk","year":"2024","unstructured":"Tilk S, Frydman J, Curtis C, Petrov DA. Cancers adapt to their mutational load by buffering protein misfolding stress. Elife. 2024;12:RP87301. https:\/\/doi.org\/10.7554\/eLife.87301.","journal-title":"Elife"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01713-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01713-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01713-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:47:12Z","timestamp":1764917232000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01713-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":233,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1713"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01713-z","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"176"}}